Short answer: no site produces more weight loss than another
There is no best GLP-1 injection site for weight loss. The US prescribing information for Zepbound, Mounjaro, Wegovy and Ozempic each states in its own pharmacokinetics section that similar drug exposure is achieved in the abdomen, the thigh and the upper arm. Same exposure means same amount of drug in your blood, which means the site cannot be a weight-loss lever. One thing does differ between the brands, and it is not absorption: on the two tirzepatide labels the upper arm is not a site you are told to use on yourself. That leaves most people two self-injection areas, not three.
Every page currently ranking for this question tells you there are three sites and that you should rotate. None of them quotes the sentence in the labels that settles the question, and none of them notices that the four labels do not say the same thing. So this page works from the labels themselves, with the wording attached, and then answers the question the wording leaves open: if the site does not change the result, what should actually decide where you inject?
What the four labels say, word for word
These are the administration sentences from the current US prescribing information for each product, quoted rather than paraphrased. The difference in the third column is the whole point of the table.
| Product | What the label says about where to inject | Upper arm on yourself? |
|---|---|---|
| Zepbound (tirzepatide) |
"Inject ZEPBOUND subcutaneously in the abdomen, thigh, or another person should inject in the back of the upper arm. Rotate injection sites with each dose." | No |
| Mounjaro (tirzepatide) |
"Inject subcutaneously in the abdomen, thigh, or have another person inject in the back of the upper arm. Rotate injection sites with each dose." | No |
| Wegovy (semaglutide) |
"Inject WEGOVY subcutaneously in the abdomen, thigh, or upper arm. The time of day and the injection site can be changed without the need for a dosage modification. Rotate injection sites with each dose." | Not restricted |
| Ozempic (semaglutide) |
"Inject subcutaneously in the abdomen, thigh, or upper arm." | Not restricted |
The part most pages get wrong: on tirzepatide you have two sites, not three
Read the Zepbound and Mounjaro sentences again. They do not list three places you may inject. They list two places you may inject and a third place another person injects for you. Lilly's own Instructions for Use for the Zepbound KwikPen repeats it as two separate bullets: "You or another person can inject the medicine in your thigh or stomach (abdomen) at least 2 inches from the belly button", then "Another person should give you the injection in the back of your upper arm."
The semaglutide labels carry no such split. Wegovy and Ozempic simply say abdomen, thigh or upper arm.
This matters for a practical reason that has nothing to do with absorption. If you inject yourself and nobody else is available on dose day, a great deal of published rotation advice quietly assumes you have three areas to cycle through. On tirzepatide you have two. A rotation plan built on three areas will run you back onto a used spot sooner than you think.
Why the back of the upper arm is different
It is the one site you cannot see while you inject and cannot reach without twisting. That is an injection technique problem, not a drug problem, which is why the restriction appears in the administration section and not in the pharmacokinetics section.
Why the site cannot change your weight loss
The labels answer this directly in section 12.3, and the sentences are almost identical across both molecules.
| Molecule | What section 12.3 says about injection site | Absolute bioavailability | Time to peak concentration |
|---|---|---|---|
| Tirzepatide (Zepbound, Mounjaro) |
"Similar exposure was achieved with subcutaneous administration of tirzepatide in the abdomen, thigh, or upper arm." | 80% | Median 24 hours (range 8 to 72 hours) |
| Semaglutide (Wegovy, Ozempic) |
"Similar exposure was achieved with subcutaneous administration of semaglutide in the abdomen, thigh, or upper arm." | 89% | 1 to 3 days post dose |
Those two numbers explain why site choice is a non-event for these drugs. Both are weekly medicines with a long half-life, roughly 5 to 6 days for tirzepatide, and both peak a day or more after the injection. Nothing about a once-weekly drug that takes 24 hours or longer to peak is sensitive to whether it started from the thigh or the abdomen. The variation people notice week to week is far more likely to be dose escalation, food, or the ordinary noise in appetite than it is the spot they chose.
Contrast that with rapid-acting insulin, where site really does matter and the abdomen is genuinely faster. That is where the "abdomen absorbs best" advice comes from. It is correct for insulin and it has been carried over to GLP-1 pages where it does not apply.
Does injecting into your stomach burn stomach fat?
No. This is the single most common misunderstanding behind the search. A subcutaneous injection puts the drug into the fat layer so that it can be absorbed into the bloodstream and act on receptors throughout the body. It does not act on the fat it passed through. Injecting into the abdomen does not target abdominal fat any more than swallowing a tablet targets your throat.
Where fat is lost is not something you direct. In the Zepbound trials, waist circumference fell by 14.0 cm on 5 mg, 17.7 cm on 10 mg and 18.5 cm on 15 mg over 72 weeks, against 4.0 cm on placebo, and every one of those patients was rotating sites as instructed.
So what does the site actually change?
Four things, none of which is how much weight you lose.
- Comfort. Subcutaneous fat depth varies by person and by site. A thinner site tends to sting more. This is individual, and it is the main reason people settle on one area.
- Whether you can do it alone. On tirzepatide, decisive. See the table above.
- Local reactions. Repeatedly using one exact spot is what the rotation instruction exists to prevent. Injection site reactions were reported in 6% to 8% of Zepbound patients depending on dose, against 2% on placebo, and in 3.2% of Mounjaro patients against 0.4% on placebo.
- Bruising. More likely where you have recently injected or where clothing rubs, such as a waistband.
The decision rule
Given all of the above, the choice collapses to something simple. Work down this list and stop at the first line that applies.
- If you are on Zepbound or Mounjaro and injecting yourself, your sites are abdomen and thigh. The upper arm is only in play on a week when someone else can do it.
- If you are on Wegovy or Ozempic, all three areas are yours, and the Wegovy label states outright that changing the site needs no dosage change.
- Among the areas available to you, pick the one that hurts least and that you can reach without contorting. That is the whole criterion.
- Then stop optimising the area and start rotating the spot, which is the part that genuinely affects your skin.
A rotation scheme that fits two sites
Every label above says to rotate with each dose. None of them says how. Here is a scheme that works with only two usable areas, which is the case most tirzepatide self-injectors are actually in.
- Treat each area as four spots, not one. For the abdomen: upper left, upper right, lower left, lower right, all staying at least 2 inches clear of the navel. For the thighs: left front upper, left front lower, right front upper, right front lower, keeping to the middle third between hip and knee.
- That gives you eight spots across two areas.
- Move to the next spot every week in a fixed order. Alternating areas week to week is fine, and so is finishing one area before switching, as long as you never return to a spot until the other seven have been used.
- At one injection a week, eight spots means roughly two months before any spot repeats.
- Skip and move on if a spot is still bruised, sore, lumpy or hardened when its turn comes. Every label tells you not to inject into skin that is damaged.
The failure mode is not choosing the wrong area. It is losing track. After a few weeks of "somewhere on the left side, I think" the rotation has quietly collapsed into two or three favourite spots, and that is the pattern that produces the lumps and the stinging.
Keeping the record the scheme depends on
A rotation plan only exists if you can answer the question "where did I inject last week" without guessing. That is the one piece of this that a tracker genuinely solves: Jabby logs each dose against a body map, so the next spot is chosen for you rather than remembered, and any soreness you record is attached to the spot and dose it followed. If you are choosing a tool for this, our GLP-1 app comparison covers what to look for.
Stop guessing where you injected last week
Jabby records each dose against a body map and picks the next site in your rotation, so an eight spot cycle stays an eight spot cycle.
Download Jabby, free on the App StoreFrequently asked questions
Is the stomach or the thigh better for GLP-1 weight loss?
Neither. Both labels state that similar exposure is achieved in the abdomen, thigh and upper arm. Choose on comfort and reach, then rotate the exact spot within whichever you pick.
Does the injection site affect how fast the medication works?
Not meaningfully. Tirzepatide peaks a median of 24 hours after the dose and semaglutide 1 to 3 days after it, with half-lives of about 5 to 6 days for tirzepatide. On that timescale the site is irrelevant.
Can I inject a GLP-1 into my upper arm myself?
On Wegovy and Ozempic the label does not restrict it. On Zepbound and Mounjaro the label specifically describes the back of the upper arm as a site another person injects for you. Ask your prescriber before treating it as a self-injection site on tirzepatide.
How far from the belly button do I need to stay?
At least 2 inches, which is the figure in Lilly's Instructions for Use for the Zepbound KwikPen.
Should I use the same area every week or alternate?
Either works. What the labels ask is that you change the site with each dose. Using the same area with a different spot inside it satisfies that, and the Zepbound Instructions for Use says so explicitly: "You may use the same area of your body but be sure to choose a different injection site in that area."
Does rotating sites improve weight loss?
There is no evidence that it does, and no label claims it. Rotation protects your skin. It is worth doing for that reason alone, because damaged tissue is the one thing that can plausibly interfere with absorption later on.
Related reading
- Best injection sites for Mounjaro, including a rotation cycle keyed to the four doses in a KwikPen
- Where is the best injection site for Wegovy, and what changes when you switch from a tirzepatide pen
- Zepbound injection site reactions, the rates by dose and how to tell a local reaction from an allergic one
- Treating a tirzepatide injection site reaction, and which of the common remedies has anything behind it
- Mounjaro vs Ozempic vs Wegovy if you are still comparing the medications themselves
- Tracking GLP-1 weight loss over the long run
Sources
- ZEPBOUND (tirzepatide) US prescribing information, Eli Lilly and Company. Sections 2.2, 6.1, 12.3, 14.1.
- MOUNJARO (tirzepatide) US prescribing information, Eli Lilly and Company. Sections 2.2, 6.1, 12.3.
- WEGOVY (semaglutide) US prescribing information, Novo Nordisk. Sections 2.1, 12.3.
- OZEMPIC (semaglutide) US prescribing information, Novo Nordisk. Sections 2.1, 12.3.
- ZEPBOUND KwikPen Instructions for Use, Eli Lilly and Company. Step 10, choosing an injection site.
- ZEPBOUND label on DailyMed, US National Library of Medicine.
This page summarises published prescribing information for general education. It is not medical advice and contains no dosing guidance. Where to inject, how much to inject and whether a medicine suits you are decisions for the clinician who prescribed it. Follow the Instructions for Use supplied with your own device.
Jabby is free on the App Store and keeps your dose history, site rotation and side effects in one record you can show your prescriber.